Drug Trial Radar · NCT06261957
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
471
Actual
Start
May 31, 2024
Primary completion
Sep 2, 2025
Study completion Sep 2, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma
Conditions
- Asthma
Interventions
Salbutamol HFA-134aDrug
100 microgram (μg) (ex-valve) at 30-second intervals per actuation
Salbutamol HFA-152aDrug
100 μg (ex-valve) at 30-second intervals per actuation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) During Run-in PeriodTime frame: From Week -1 up to randomization (Day 1) during Run-in period
- Number of Participants With Adverse Events (AEs) During Treatment PeriodTime frame: From randomization (Day 1) up to Week 13 (Follow up) during treatment period
Locations
102 sites in 13 countries. Site status is shown where the registry gives one.
GSK Investigational Site
North Hollywood, California
GSK Investigational Site
San Mateo, California
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
DeLand, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Naples, Florida
GSK Investigational Site
Plantation, Florida
GSK Investigational Site
Winter Park, Florida
GSK Investigational Site
Rincon, Georgia
GSK Investigational Site
Stonecrest, Georgia
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Owensboro, Kentucky
GSK Investigational Site
Fall River, Massachusetts
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Minneota, Minnesota
GSK Investigational Site
Olive Branch, Mississippi
GSK Investigational Site
Columbia, Missouri
GSK Investigational Site
Henderson, Nevada
GSK Investigational Site
Jersey City, New Jersey
GSK Investigational Site
Riverdale, New Jersey
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
Asheville, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Dublin, Ohio
GSK Investigational Site
Medford, Oregon
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Pottstown, Pennsylvania
GSK Investigational Site
Rock Hill, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
Union, South Carolina
GSK Investigational Site
Sugar Land, Texas
GSK Investigational Site
Tomball, Texas
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.